BCG

[키워드] 1:1 24 hour Administered administration age All participant allergy anti-cytokine therapy approved asked Bacterial infection BCG BCG vaccination blinded to treatment block Bone marrow Chemotherapy component Controlled trial COVID-19 COVID-19 pandemic criteria cumulative current daily dose Day defined Denmark Direct dissemination dose Effect element eligible ENhance EudraCT excluded exclusion group HCW Health care Health care worker HIV-1 hospital Hospital admission hospitals Human immunodeficiency virus Immunocompromised immunodeficiency incidence Inclusion infected with SARS-CoV-2 Infection infections Infectious disease injection Intervention intravenous lymphoma malignancy Medicine meet morbidity and mortality mycobacterial Mycobacterium tuberculosis NaCl solution non-specific not blinded number participant physician Placebo Prednisone Prevent protective effect protocol random randomisation randomised randomised controlled trial receive recruit reduce reductions in Registered reported resuspended Sample secondary Serious Adverse Event severity of COVID-19 Sex solid organ transplantation steroid Stratification study participant Study protocol subject subjects susceptibility suspicion Treatment Trial Tuberculosis Vaccine Vaccines website
[DOI] 10.1186/s13063-020-04714-3 PMC 바로가기 [Article Type] Letter